Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 18/20 | 0.53 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | GPX4 | P36969 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.42 |
| ▸ | BRSK1 | Q8TDC3 | 1/20 | 0.42 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1771743 | 0.82 | AR (0.48) | ARMAP4K4PIM1GPX4GSK3B | |
| SCHEMBL13216933 | 0.81 | AR (0.47) | ARMAP4K4PIM1GPX4GSK3B | |
| SCHEMBL2741022 | 0.81 | AR (0.63) | ARMAP4K4PIM1GPX4GSK3B | |
| SCHEMBL1771467 | 0.78 | AR (0.54) | AR | |
| SCHEMBL2741026 | 0.78 | PDPK1 (0.44) | ARPARP1 | |
| SCHEMBL1772838 | 0.76 | AR (0.49) | AR | |
| SCHEMBL6023684 | 0.76 | TNKS2 (0.52) | ARPARP1 | |
| SCHEMBL1771689 | 0.76 | AR (0.51) | AR | |
| SCHEMBL13237211 | 0.74 | CYP1A2 (0.39) | ARPARP1PIM3 | |
| SCHEMBL1772177 | 0.73 | AR (0.50) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11358931-B2 | Selective androgen receptor modulators (SARMs) and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2022-06-14 | — | — | US | disclosed |
| US-20200361866-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2020-11-19 | — | — | US | disclosed |
| US-20100210678-A1 | Tricyclic androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2010-08-19 | — | — | US | disclosed |
| US-20100210678-A1 | Tricyclic androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2010-08-19 | — | — | US | disclosed |
| US-7727980-B2 | Tricyclic androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2010-06-01 | — | — | US | disclosed |
| US-7727980-B2 | Tricyclic androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2010-06-01 | — | — | US | disclosed |
| US-7727980-B2 | Tricyclic androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2010-06-01 | — | — | US | disclosed |
| US-20070293528-A9 | Tricyclic androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-20070293528-A9 | Tricyclic androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-20070293528-A9 | Tricyclic androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-20060128740-A1 | Tricyclic androgen receptor modulator compounds and methods | ZHI LIN | 2006-06-15 | — | — | US | disclosed |
| US-7026484-B2 | For therapy of cancer | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2006-04-11 | — | — | US | disclosed |
| EP-1363909-A2 | TRICYCLIC ANDROGEN RECEPTOR MODULATOR COMPOUNDS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20020183346-A1 | Tricyclic androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2002-12-05 | — | — | US | disclosed |
| WO-2002066475-A2 | TRICYCLIC ANDROGEN RECEPTOR MODULATOR COMPOUNDS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361866-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | AR, NR5A1, SHBG | AR 1/4885PARP1 2785/4885MAP4K4 875/4885 |
| US-11358931-B2 | Selective androgen receptor modulators (SARMs) and uses thereof | AR, NR5A1, SHBG | AR 1/4885PARP1 2979/4885MAP4K4 1055/4885 |
| US-20020183346-A1 | Tricyclic androgen receptor modulator compounds and methods | AR, NR5A1, ESRRA | AR 1/4885PARP1 2215/4885MAP4K4 1470/4885 |
| US-20070293528-A9 | Tricyclic androgen receptor modulator compounds and methods | AR, NR5A1, ESRRA | AR 1/4885PARP1 2215/4885MAP4K4 1470/4885 |
| US-20100210678-A1 | Tricyclic androgen receptor modulator compounds and methods | AR, NR5A1, ESRRA | AR 1/4885PARP1 2999/4885MAP4K4 1968/4885 |
| US-20060128740-A1 | Tricyclic androgen receptor modulator compounds and methods | AR, NR5A1, ESRRA | AR 1/4885PARP1 2215/4885MAP4K4 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.